ISTH 2022 Congress
Hemophilia and Rare Bleeding Disorders » Novel Biotherapeutics in Hemophilia
Theme Navigation
- ISTH 2022 Congress
- Hemophilia and Rare Bleeding Disorders
- Novel Biotherapeutics in Hemophilia
- Hemophilia and Rare Bleeding Disorders
-
Abstract Number: PB0218
Adaptative methods using one-stage and chromogenic substrate assays for the quantitative measurement of Mim8 in human plasma
-
Abstract Number: PB0225
An engineered factor X variant as a novel by-passing agent for hemophilia
-
Abstract Number: PB0222
Assay of modified factor VIII is modulated by von Willebrand factor. What should we measure ?
-
Abstract Number: PB0226
Assay of the factor VIIIa mimetic, Mim8, using one-stage clotting assay requires a product-specific reference material
-
Abstract Number: PB0215
Efficacy, effectiveness, and safety of emicizumab for the treatment of people with hemophilia A: a systematic review
-
Abstract Number: PB0216
Efficacy, effectiveness, and safety of extended half-life factor VIII products for the treatment of hemophilia A: protocol of a systematic review
-
Abstract Number: VPB0230
Emicizumab treatment of 4 patients with severe hemophilia A and inhibitors in pediatric age – Resource management to minimize economic costs while maintaining the quality of clinical follow-up
-
Abstract Number: PB0229
Emicizumab: In-house method validation
-
Abstract Number: PB0220
Evaluation of four different reagents on the coagulation analyzers STAR MAX® and ATELLICA® COAG 360 for Emicizumab concentration measurement in severe hemophilia A patients
-
Abstract Number: PB0224
Evaluation of thrombin generation and emicizumab concentration in a cohort of severe Hemophilia A patients with and without inhibitor during emicizumab prophylaxis
-
Abstract Number: OC 40.1
FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics, and Efficacy
-
Abstract Number: PB0217
Impacts of Mim8 on routine coagulation assays, on intrinsic pathway coagulation factor assays and on thrombophilia coagulation tests
-
Abstract Number: OC 50.3
Improved Procoagulant Activity of Hemophilia B Causing Dysfunctional Factor IX Variants with Factor VIII Mimetics
-
Abstract Number: VPB0228
Investigation of properties of macropore silica sorbents and active dyes as ligands suitable for purification of factor VIII coagulation
-
Abstract Number: VPB0227
Laboratory monitoring in haemophilia A patients with factor VIII inhibitor treated with emicizumab
-
Abstract Number: PB0223
Mim8 does not affect FVIII function in hemophilia A
-
Abstract Number: OC 50.5
Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors
-
Abstract Number: PB0221
Neutralizing antidrug antibody to emicizumab: Detailed laboratory evaluation and review of the literature